Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Epithelial growth factor receptor interacting agents.

Jose Baselga1, Joan Albanell

  • 1Medical Oncology Service, Hospital General Universitari Vall d'Hebron, Paseo Vall d'Hebron 119-129, 08035 Barcelona, Spain. baselga@hg.vhebron.es

Hematology/Oncology Clinics of North America
|January 7, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cancer-associated fibroblast-derived protein S100-A11 influences the response to anti-HER2 therapies in HER2-positive breast cancer.

Neoplasia (New York, N.Y.)·2026
Same author

Response to the letter to the editor entitled "The precision of a report on precision".

Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·2026
Same author

Estrogen receptor signaling drives immune evasion and immunotherapy resistance in HR+ breast cancer.

The Journal of clinical investigation·2025
Same author

Implementation of the precision oncology program in catalonia's public health system: results, lessons learned, and future prospects.

Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·2025
Same author

TIM3<sup>+</sup> breast cancer cells license immune evasion during micrometastasis outbreak.

Cancer cell·2025
Same author

Biomarkers of palbociclib response in hormone receptor-positive advanced breast cancer from the PARSIFAL trial.

NPJ breast cancer·2025
Same journal

Palliative Therapy for Liver and Biliary Neoplasms.

Hematology/oncology clinics of North America·2026
Same journal

Ablative Therapies for Liver Tumors.

Hematology/oncology clinics of North America·2026
Same journal

Pathology of Liver and Biliary Neoplasms.

Hematology/oncology clinics of North America·2026
Same journal

Minimally Invasive Surgery for Liver and Biliary Tract Neoplasms.

Hematology/oncology clinics of North America·2026
Same journal

Surgical Considerations for Primary Liver Neoplasms.

Hematology/oncology clinics of North America·2026
Same journal

Systemic Therapy for Biliary and Liver Neoplasms: Chemotherapy and Immunotherapy.

Hematology/oncology clinics of North America·2026
See all related articles

Anti-epidermal growth factor receptor (EGFR) therapies show promise in cancer treatment. Targeted drugs, including TK inhibitors and monoclonal antibodies, demonstrate antitumor activity across various cancer types.

Area of Science:

  • Oncology
  • Molecular Biology
  • Drug Development

Background:

  • Epidermal growth factor receptor (EGFR) is a key target in cancer therapy.
  • Anti-EGFR therapies encompass tyrosine kinase (TK) inhibitors and monoclonal antibodies.
  • Several anti-EGFR agents are in various stages of clinical development.

Purpose of the Study:

  • To review the established promise of anti-EGFR-targeted therapies.
  • To highlight the antitumor activity and mechanisms of action of these agents.
  • To validate EGFR as a therapeutic target in oncology.

Main Methods:

  • Review of preclinical and clinical data on anti-EGFR compounds.
  • Categorization of TK inhibitors by receptor specificity and binding reversibility.

Related Experiment Videos

  • Classification of monoclonal antibodies by type (chimeric, humanized, bispecific).

    • Main Results:

    • Tyrosine kinase inhibitors (ZD1839, OSI-774) show antitumor activity in multiple cancer types.
    • The monoclonal antibody IMC-C225 demonstrates efficacy in reversing chemotherapy resistance.
    • Anti-EGFR agents exhibit activity in non-small cell lung cancer, prostate, colorectal, ovarian, renal cell, and head and neck cancers.

    Conclusions:

    • EGFR is a validated target for cancer therapy based on diverse clinical data.
    • Ongoing studies are crucial to establish the role of anti-EGFR therapies in current cancer treatment paradigms.
    • Anti-EGFR targeted therapies represent a promising avenue for improving cancer patient outcomes.